Bevacizumab

Drug #2200

Bevacizumab is a multikinase inhibitor. It slows the growth of cancer cells, by blocking certain enzymes in the body that may be involved in the growth and spread of cancer cells, and spread in the body. It is usually given as part of a combination of cancer.

← Previous drug Next drug →

Primary Characteristics

Molecular Weight: 149 · Non-proprietary name: Bevacizumab.

Pharmacokinetics

None recorded.

Indications

Bevacizumab is primarily indicated in conditions like Brain tumors, Breast cancer, Lung cancer, Metastatic colorectal cancer.

Contraindications

Bevacizumab is contraindicated in conditions like Hypertension, Wounds, Blood clot, History of stroke.

Dosage

None recorded.

Drug Interactions

None recorded.

Side Effects

Bevacizumab produces potentially life-threatening effects which include Blood in stools, Blood in stoolsvomitings, Sudden numbness. Careful monitoring is needed with proper medical management.

Bevacizumab is known to cause more or less tolerable side effects which are usually transient. These include Chest pain, Chills, Dizziness, Increase in heart rate , Itching, Light headedness, Nausea, Sweating , Wheezing .

Warnings / Precautions

Avoid having surgery while you are being treated with bevacizumab. You may have problems with wound healing, which could result in bleeding or infection. If you need to have any type of surgery, you will need to stop receiving bevacizumab for at least 4 weeks while your surgical incision heals.

Available Brands

None recorded.

Drug Classification

1.8.2 — Cytotoxic (anti-neoplastic) drugs